StockNews.AI
ALGS
StockNews.AI
13 days

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results

1. ALGS starts Phase 2 study of ALG-000184 for HBV infection. 2. Positive Phase 1 data shows potential to replace current HBV treatments. 3. Significant reductions in liver fat reported for ALG-055009 in Phase 2a study. 4. Cash reserves of $122.9 million expected to fund operations into 2026. 5. Increased research efforts and discussions for potential partnerships underway.

16m saved
Insight
Article

FAQ

Why Bullish?

The initiation of successful Phase 2 trials and positive interim data enhances investor confidence, akin to past successful biotech initiations. Historical examples like Gilead Sciences' HBV developments led to price increases during trial announcements.

How important is it?

The advancements in clinical trials and financial health directly relate to future revenue potential, making the article highly relevant for stakeholders.

Why Long Term?

Ongoing trials and expected topline data in 2027 indicate sustained long-term development interest, which can support prolonged valuation growth, similar to other biotech firms boosting valuations before product launch.

Related Companies

GILDMRNAVRTX
August 06, 2025 16:05 ET  | Source: Aligos Therapeutics SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the second quarter 2025. “Initiation of the Phase 2 B-SUPREME study of ALG-000184 is well underway with regulatory approvals across a number of countries, including the US, China, Canada, Taiwan, UK, New Zealand, and Moldova,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “Site activations are in progress, subjects are being screened, and we expect dosing to commence in the coming weeks. This pertinent study is the next step in our journey to potentially deliver better therapies for patients living with HBV infection and create value for our stakeholders. The Phase 1 data showcasing 96 weeks of treatment presented at the EASL meeting suggests that ALG-000184 has the potential to replace standard of care treatment for chronic suppression of HBV infection and may become the backbone of treatments aimed at a functional cure. We remain excited about the potential of ALG-000184 and the entirety of our pipeline, including ALG-055009 which remains in discussions with potential partners.” Recent Business Progress Pipeline Updates       ALG-000184: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (HBV) infection The Phase 2 B-SUPREME study (NCT04746183) of ALG-000184 in subjects with chronic HBV infection recently began obtaining regulatory approvals, activating global sites, and screening subjects. Dosing is expected to commence in the coming weeks. The study is designed as a randomized, double-blind, active-controlled multicenter study evaluating the safety and efficacy of ALG-000184 monotherapy compared with tenofovir disoproxil fumarate in approximately 200 untreated HBeAg+ and HBeAg- adult subjects with chronic HBV infection for 48 weeks. The primary endpoint in the HBeAg+ part will be HBV DNA

Related News